@article{8cbf249f4b3b46b28ec06519eeb5a4bd,
title = "Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience",
abstract = "Imatinib mesylate (IM) is used for the management of childhood chronic myeloid leukaemia (CML). The most effective dosage of IM and its long-term efficacy in children are not well defined. The purpose of this multicentre study is to report on the long-term results of high-dose IM (340 mg/m2 /d) in CML patients in chronic phase (CP-CML) aged ",
keywords = "BCR-ABL1, childhood, chronic myeloid leukaemia, imatinib, tyrosine kinase inhibitors",
author = "Fiorina Giona and Putti, {Maria C.} and Concetta Micalizzi and Giuseppe Menna and Moleti, {Maria L.} and Nicola Santoro and Grazia Iaria and Saverio Ladogana and Roberta Burnelli and Caterina Consarino and Stefania Varotto and Francesca Tucci and Chiara Messina and Mauro Nanni and Daniela Diverio and Andrea Biondi and Andrea Pession and Franco Locatelli and Alfonso Piciocchi and Enrico Gottardi and Giuseppe Saglio and Robin Fo{\`a}",
year = "2015",
month = aug,
day = "1",
doi = "10.1111/bjh.13453",
language = "English",
volume = "170",
pages = "398--407",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "3",
}